CC
SRPT icon

Cipher Capital’s Sarepta Therapeutics SRPT Stock Holding History

Cipher Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$552K Sell
4,260
-5,212
-55% -$638K 0.26% 135
2023
Q4 		$913K Buy
9,472
+5,084
+116% +$488K 0.3% 95
2023
Q3 		$532K Buy
+4,388
New +$496K 0.38% 81

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Cipher Capital's SRPT Position: Q1 2024 in Review

Cipher Capital reduced its Sarepta Therapeutics (SRPT) stake by 55% in Q1 2024, selling an estimated $638K and leaving 4,260 shares worth $552K. The position accounts for 0.26% of the portfolio, ranked #135.

Cipher Capital first reported a position in SRPT in Q3 2023 and has held it in 3 quarters since. The position peaked at $913K in Q4 2023. 414 funds tracked by Wall St. Rank hold SRPT as of Q1 2024.

  • Cipher Capital held 4,260 shares of Sarepta Therapeutics worth $552K as of Q1 2024.
  • Cipher Capital sold 5,212 Sarepta Therapeutics shares in Q1 2024, an estimated $638K.
  • Sarepta Therapeutics made up 0.26% of Cipher Capital's portfolio in Q1 2024, its #135 holding.
  • Cipher Capital first reported a position in Sarepta Therapeutics in Q3 2023 and has held it in 3 quarters since.
  • Cipher Capital's Sarepta Therapeutics position peaked at $913K in Q4 2023.
  • 414 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2024.

Based on Cipher Capital's 13F filing for Q1 2024, filed 15 May 2024.